This is the authors' abstract. We don't add key points for this paper.
The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Vincent et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: